Abstract 172P
Background
Successful treatment with adjuvant osimertinib depends on adherence to the recommended treatment duration (3 years). This study aimed to identify drivers and barriers to adherence of osimertinib from patients’ and healthcare professionals’ (HCPs’) perspectives.
Methods
Patients with completely resected stage IB-IIIA epidermal growth factor receptor (EGFR)-mutated NSCLC prescribed adjuvant osimertinib in the past 12 months and HCP prescribers were interviewed between July and November 2023. Interview transcripts were thematically analysed using NVivo software. Drivers and barriers to adherence were mapped onto the COM-B model of behaviour (B) components of capability (C), opportunity (O), and motivation (M).
Results
38 patients (20 USA, 10 Germany and 8 UK) and 6 oncologists (2 USA, 2 Germany and 2 UK) were interviewed. The median duration of treatment was 5.5 months (range 1–20 months) at the time of the interview. Three patients had discontinued osimertinib at the time of the interview. Of those taking osimertinib (n=35), 32 (91.4%) reported taking it as prescribed. Drivers of adherence reported by patients could be categorised in terms of capability (understanding the treatment rationale; use of strategies to manage forgetting and side effects), motivation (perceived benefits of osimertinib and importance of adherence), and opportunity (HCP communication; social support). All HCPs recommended taking osimertinib for 3 years. This was driven by capability (patient communication; clinical experience), motivation (belief that osimertinib is safe and effective) and opportunity (trial results, guidelines and insurance coverage). Reasons reported by HCPs for discontinuing treatment were side effects, disease progression and patient decision.
Conclusions
This study showed that patient communication, strategies for managing forgetting and side effects as well as social support are key drivers/barriers to adherence with adjuvant osimertinib. The findings obtained can guide the development of patient support interventions. Further research is needed to examine longer-term adherence patterns and determinants.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
N. Florez: Financial Interests, Personal, Advisory Board: AstraZeneca, Merck, Mirati, Takeda, Neogenomics, Pfizer; Financial Interests, Personal, Other, Presentation: BMS; Financial Interests, Personal, Other, Consulting/advisory role: Daiichi Sankyo, Genentech, Regeneron. V. Cooper: Financial Interests, Personal, Full or part-time Employment: Sprout Health Solutions; Financial Interests, Institutional, Other, Corporate sponsored research: AstraZeneca. Y. Liang, R.J. Salomonsen, M. Sandelin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. L. Eliasson: Financial Interests, Personal, Member of Board of Directors: Sprout Health Solutions; Financial Interests, Institutional, Other, Corporate sponsored research: AstraZeneca. A. Moore: Financial Interests, Personal, Advisory Board, All honoraria paid to LUNGevity, not me personally.: AstraZeneca, Exact Sciences; Financial Interests, Personal, Advisory Board, All honoraria paid to LUNGevity, not me personally: Novartis; Financial Interests, Personal, Full or part-time Employment, VP, Global Engagement and Research Partnerships: LUNGevity Foundation; Financial Interests, Personal, Member of Board of Directors, Unpaid: NTRKers. J. Rotow: Financial Interests, Personal, Advisory Board: AstraZeneca, BioAtla, BMS, Boehringer Ingelheim, Daiichi Sankyo, Genentech, G1 Therapeutics, Gilead, Johnson & Johnson, Jazz, Merus, Novocure, Pfizer, Summit, Takeda; Financial Interests, Personal, Invited Speaker: AstraZeneca, Daiichi Sankyo, Pfizer, Regeneron; Financial Interests, Institutional, Invited Speaker: AbbVie, AstraZeneca, Bicycle Therapeutics, BioAtla, Blueprint Medicines, Daiichi Sankyo, Enliven, EpimAb, Lilly, ORIC, RedCloud, Summit, Black Diamond, Synthekine, ImmunityBio.